Metastatic Carcinoma Clinical Trial
Official title:
Phase II Study of Docetaxel and Gemcitabine in Previously Treated Metastatic Esophageal Squamous Cell Cancer
Gemcitabine is a novel analog of the nucleoside deoxycytidine that acts via inhibition of
DNA synthesis.Docetaxel is a semisynthetic taxane and promotes microtubule assembly and
inhibits microtubule depolymerization.
In this study, patients received gemcitabine 900 mg/m2 on days 1 and 8 plus docetaxel 100
mg/m2 on day 8 with G-CSF support every 3 week.
n/a
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02605811 -
Temozolomide in Preventing Brain Metastases in Small Cell Lung Cancer
|
Phase 2 | |
| Terminated |
NCT02960282 -
Gut Microbiome in Fecal Samples From Patients With Metastatic Cancer Undergoing Chemotherapy or Immunotherapy
|
||
| Completed |
NCT01320241 -
Radiation Stent Versus Self-expanding Metallic Stents (SEMS) for Palliative Treatment of Malignant Biliary Stricture
|
Phase 2 | |
| Active, not recruiting |
NCT04939246 -
Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) in One Fraction
|
N/A | |
| Completed |
NCT02192346 -
α-TEA in Advanced Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT04376502 -
Immune Checkpoint Inhibitor and MR-guided SBRT for Limited Progressive Metastatic Carcinoma.
|
N/A | |
| Active, not recruiting |
NCT02730923 -
Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA)
|
Phase 1/Phase 2 |